FDA Brief

Warning letters Drugs

FDA warning letter to

Betone S.A. de C.V.

High riskIssued Mar 21, 2024Posted Apr 2, 2024Center for Drug Evaluation and Research | CDER

FDA warns Betone S.A. de C.V. over manufacturing violations for OTC antiseptic wipes, including subpotent active and missing glycerin safety tests.

What happened

FDA inspected Betone S.A. de C.V.'s drug manufacturing facility from November 6 to 10, 2023, and reviewed the company's December 1, 2023 response. FDA found violations of current good manufacturing practice (CGMP), the rules for drug manufacturing: missing release testing, subpotent formulation, inadequate component testing including glycerin for DEG/EG, and insufficient stability testing.

What FDA found

  1. The company did not test each batch for identity and strength of the active ingredient before releasing it.

    21 CFR 211.165(a)
  2. The company made wipes with less active ingredient than the labeled amount.

    21 CFR 211.101(a)
  3. The company did not adequately test incoming components for identity and conformity, and did not establish the reliability of suppliers' certificates of analysis.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  4. The company did not perform the USP identity test on each glycerin shipment or lot to detect diethylene glycol (DEG) or ethylene glycol (EG).

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  5. The company did not have stability testing adequate to support the expiration dates on its distributed drug products.

    21 CFR 211.137(a)
  6. The label for DODY’S Antiseptic Hand Sanitizer Wipes suggests use as an antiseptic wash, which conflicts with wipe directions and dosage form.

    section 505G of the FD&C Act

What FDA wants

Respond in writing within 15 working days with corrective actions and preventive actions. Provide DEG and EG test results from retained high-risk component lots, or testing of implicated finished batches, no later than 30 calendar days from the date of the letter.

Who should pay attention

  • brands that buy OTC wipes from this contract manufacturer
  • retailers and distributors selling DODY’S antiseptic wipes
  • companies sourcing glycerin or other high-risk components from suppliers that rely on certificates of analysis

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk